to go to the previous page
Strategies for Implementing Dried Blood Spot Drug Development and How the Technology Supports the 3Rs Principles
Thursday, June 28, 2012
10:45 AM to 12:15 PM
Fumin Li, Covance, Inc., United States
Associate Director in the Projects, Standards and Innovations group of Drug Disposition within DSAR at sanofi supporting innovations initiatives in DBS Technology, biopharmaceutics strategies for development of orally administered compounds and expert support for nonclinical ADME activities.
Dr. John A. Dunn received his PhD in chemistry from the University of SC. He began his career at Burroughs Wellcome (1990-1995), Glaxo Wellcome (1995-2000), and GlaxoSmithKline (2001-present). He is currently the US Director for the bioanalytical group in DMPK at GSK.
Enaksha Wickremsinhe, Eli Lilly and Company, United States
Dried blood spot (DBS) sampling is gaining momentum as an alternative to plasma in support of drug discovery and development. DBS provides significant ethical benefits with reduced animal usage, using the 3Rs principle (animal reduction, refinement, and replacement), and higher data quality in safety assessment.
Discuss the backgrounds of dried blood spot (DBS) and the 3Rs principle (animal reduction, refinement and replacement)
Describe DBS nonclinical and clinical benefits
Evaluate the DBS impact on drug discovery and development.
Audio Synchronized to PowerPoint